[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

SG11202104637VA - MARROW INFILTRATING LYMPHOCYTES (MILs) EXPRESSING CHIMERIC ANTIGEN RECEPTORS (CAR), METHOD OF MANUFACTURING SAME, AND METHOD OF USING IN THERAPY - Google Patents

MARROW INFILTRATING LYMPHOCYTES (MILs) EXPRESSING CHIMERIC ANTIGEN RECEPTORS (CAR), METHOD OF MANUFACTURING SAME, AND METHOD OF USING IN THERAPY

Info

Publication number
SG11202104637VA
SG11202104637VA SG11202104637VA SG11202104637VA SG11202104637VA SG 11202104637V A SG11202104637V A SG 11202104637VA SG 11202104637V A SG11202104637V A SG 11202104637VA SG 11202104637V A SG11202104637V A SG 11202104637VA SG 11202104637V A SG11202104637V A SG 11202104637VA
Authority
SG
Singapore
Prior art keywords
mils
therapy
car
chimeric antigen
manufacturing same
Prior art date
Application number
SG11202104637VA
Inventor
Kimberly Noonan
Ivan Borrello
Eric Lutz
Lakshmi Rudraraju
Srikanta Jana
Ido Weiss
Valentina Hoyos
Original Assignee
Windmil Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Windmil Therapeutics Inc filed Critical Windmil Therapeutics Inc
Publication of SG11202104637VA publication Critical patent/SG11202104637VA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0634Cells from the blood or the immune system
    • C12N5/0636T lymphocytes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48Blood cells, e.g. leukemia or lymphoma
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K39/4611
    • A61K39/4631
    • A61K39/464412
    • A61K39/464417
    • A61K39/464426
    • A61K39/464429
    • A61K39/464441
    • A61K39/464482
    • A61K39/464495
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503Immunoglobulin superfamily
    • C07K14/7051T-cell receptor (TcR)-CD3 complex
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503Immunoglobulin superfamily
    • C07K14/70521CD28, CD152
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503Immunoglobulin superfamily
    • C07K14/70532B7 molecules, e.g. CD80, CD86
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069Reproductive system, e.g. ovaria, uterus, testes, prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/57Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00Preparations for use in therapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/60Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622Single chain antibody (scFv)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/01Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/33Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00Specific components of cell culture medium
    • C12N2500/02Atmosphere, e.g. low oxygen conditions
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20Cytokines; Chemokines
    • C12N2501/23Interleukins [IL]
    • C12N2501/2302Interleukin-2 (IL-2)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Developmental Biology & Embryology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Virology (AREA)
  • Hospice & Palliative Care (AREA)
SG11202104637VA 2018-11-30 2019-11-27 MARROW INFILTRATING LYMPHOCYTES (MILs) EXPRESSING CHIMERIC ANTIGEN RECEPTORS (CAR), METHOD OF MANUFACTURING SAME, AND METHOD OF USING IN THERAPY SG11202104637VA (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862773384P 2018-11-30 2018-11-30
US201962828592P 2019-04-03 2019-04-03
US201962930886P 2019-11-05 2019-11-05
PCT/US2019/063605 WO2020113000A1 (en) 2018-11-30 2019-11-27 MARROW INFILTRATING LYMPHOCYTES (MILs) EXPRESSING CHIMERIC ANTIGEN RECEPTORS (CAR), METHOD OF MANUFACTURING SAME, AND METHOD OF USING IN THERAPY

Publications (1)

Publication Number Publication Date
SG11202104637VA true SG11202104637VA (en) 2021-06-29

Family

ID=70853127

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202104637VA SG11202104637VA (en) 2018-11-30 2019-11-27 MARROW INFILTRATING LYMPHOCYTES (MILs) EXPRESSING CHIMERIC ANTIGEN RECEPTORS (CAR), METHOD OF MANUFACTURING SAME, AND METHOD OF USING IN THERAPY

Country Status (11)

Country Link
US (2) US20220257650A1 (en)
EP (1) EP3870191A4 (en)
JP (1) JP2022513687A (en)
KR (1) KR20210098485A (en)
CN (1) CN113396215A (en)
AU (1) AU2019387242A1 (en)
CA (1) CA3120323A1 (en)
IL (1) IL283073A (en)
MX (1) MX2021006399A (en)
SG (1) SG11202104637VA (en)
WO (1) WO2020113000A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107109364A (en) * 2014-09-04 2017-08-29 约翰霍普金斯大学 Anoxic and the activation of the bone marrow infiltration lymphocyte under normal oxygen alternation condition
CN109735558B (en) * 2018-12-12 2022-04-15 中南大学 Recombinant CAR19-IL24 gene, lentiviral vector, CAR19-IL24-T cell and application
WO2022066872A1 (en) * 2020-09-24 2022-03-31 Windmil Therapeutics, Inc. Marrow infiltrating lymphocytes (mils) expressing t cell receptors, methods of manufacturing same, and method of using in therapy
WO2022098982A1 (en) * 2020-11-05 2022-05-12 Windmil Therapeutics, Inc. Breast cancer specific marrow infiltrating lymphocytes and uses thereof
WO2022098977A1 (en) * 2020-11-05 2022-05-12 Windmil Therapeutics, Inc. Head and neck cancer specific marrow infiltrating lymphocytes and uses thereof
IL309674A (en) * 2021-06-28 2024-02-01 Meridian Therapeutics Inc Compositions and methods of treating plasma cell disorders including multiple myeloma with a vaccine composition and myeloma-specific car-t cells

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107109364A (en) * 2014-09-04 2017-08-29 约翰霍普金斯大学 Anoxic and the activation of the bone marrow infiltration lymphocyte under normal oxygen alternation condition
SI3230321T1 (en) * 2014-12-12 2019-12-31 Bluebird Bio, Inc. Bcma chimeric antigen receptors
WO2016172583A1 (en) * 2015-04-23 2016-10-27 Novartis Ag Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
CN108137707A (en) * 2015-06-29 2018-06-08 约翰霍普金斯大学 Immunologic test point Chimerical receptor therapy
MA42902A (en) * 2015-07-08 2018-05-16 Univ Johns Hopkins MARINAL-INFILTRATING LYMPHOCYTES (MIL) AS A SOURCE OF T-LYMPHOCYTES FOR CHEMERIC ANTIGEN RECEPTOR (CAR) THERAPY
WO2017190100A1 (en) * 2016-04-28 2017-11-02 The Trustees Of Dartmouth College Nucleic acid constructs for co-expression of chimeric antigen receptor and transcription factor, cells containing and therapeutic use thereof
CA3083118A1 (en) * 2017-11-22 2019-05-31 Iovance Biotherapeutics, Inc. Expansion of peripheral blood lymphocytes (pbls) from peripheral blood
AU2019240420A1 (en) * 2018-03-22 2020-06-25 Windmil Therapeutics, Inc. Prostate cancer specific marrow infiltrating lymphocytes and uses thereof

Also Published As

Publication number Publication date
EP3870191A4 (en) 2022-09-28
US20210154233A1 (en) 2021-05-27
CA3120323A1 (en) 2020-06-04
US20220257650A1 (en) 2022-08-18
MX2021006399A (en) 2021-07-15
AU2019387242A1 (en) 2021-06-03
KR20210098485A (en) 2021-08-10
EP3870191A1 (en) 2021-09-01
WO2020113000A1 (en) 2020-06-04
IL283073A (en) 2021-06-30
CN113396215A (en) 2021-09-14
JP2022513687A (en) 2022-02-09

Similar Documents

Publication Publication Date Title
IL283073A (en) Marrow infiltrating lymphocytes (mils) expressing chimeric antigen receptors (car), method of manufacturing same, and method of using in therapy
IL266230A (en) Antibodies directed against t cell immunoglobulin and mucin protein 3 (tim-3)
HK1251150A1 (en) Antibodies directed against t cell immunoglobulin and mucin protein 3 (tim-3)
ZA202208807B (en) Anti-tigit antibodies and usage method
ZA201900792B (en) Anti-pd-1 antibodies, method for producing same and method for using same
IL269656A (en) Erbb-2 and erbb3 binding bispecific antibodies for use in the treatment of cells that have an nrg1 fusion gene
IL283530A (en) Anti-pd-l1/anti-4-1bb bispecific antibodies and uses thereof
IL271179A (en) Method of manufacturing bispecific antibodies, bispecific antibodies and therapeutic use of such antibodies
SG11202003782XA (en) Triple-chain antibody, method for preparation and use thereof
MX2017017083A (en) Marrow infiltrating lymphocytes (mils) as a source of t-cells for chimeric antigen receptor (car) therapy.
SG10201912494TA (en) Anti-cd3-binding domains and antibodies comprising them, and methods for their generation and use
HK1248529A1 (en) Multi-specific antibodies with affinity for human a33 antigen and dota metal complex and uses thereof
IL263627A (en) Chimeric antigen receptors (cars) specific for muc1 and methods for their use
SG11202100308YA (en) Bonding composition, conductor bonding structure, and method for producing same
GB202103876D0 (en) Alumina sol-silane composite material, preparation method and application thereof
IL278862A (en) Monospecific and multispecifc anti-tmeff2 antibodies and their uses
IL288607A (en) High affinity anti-cd3 antibodies, and methods for their generation and use
PT3572156T (en) Method for sorting luggage in an airport
ZA202003858B (en) Monoclonal antibodies and methods for using same
IL310780A (en) Anti-b7-h4/anti-4-1bb bispecific antibodies and use thereof
PL3643678T3 (en) Sulfur-carbon composite and method for preparing same
EP3375875A4 (en) SEPARATING AGENT FOR HUMAN SERUM-DERIVED IgG POLYCLONAL ANTIBODIES, AND METHOD FOR SEPARATING HUMAN SERUM-DERIVED IgG POLYCLONAL ANTIBODIES USING SAME
EP4058363A4 (en) Integrated pick, place, and forming apparatus and method for composite charges over complex geometries
IL289158A (en) Anti-cd123 antibodies, anti-cd123 chimeric antigen receptors and anti-cd123 chimeric antigen receptors t cells
EP3572169A4 (en) Copper porous body, copper porous composite member, method for producing copper porous body, and method for producing copper porous composite member